Navigation Links
Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Date:1/22/2008

patients co-infected with HCV and HIV.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to the risk that the company will experience delays or difficulties in enrolling patients in the study and the risk that the results from this trial will not be consistent with the results of prior trials or preclinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in devel
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...th Hypophosphatasia Treated With ENB-0040 at Child... , , MONTREAL, Dec. 1 Enobi...used on developing novel therapeutics for serious ...ant patient in its clinical program for hypophosph...eplacement Therapy (ERT) with ENB-0040 for the tre...
(Date:12/1/2008)...D, Denmark, December 1 F...th the intent to procure an MVA-based,third gene...nt Services,Canada, on behalf of the Canadian Dep...ct to Bavarian Nordic for the delivery of IMVAMUNE...se IMVAMUNE(R) as part of the,country,s bio-prepa...
(Date:11/30/2008)...CHICAGO, Dec. 1 Older a...al blood flow and a greater number of small blood ...ted today at the annual meeting of the Radiologica... study, conducted at the University of North Caro...re brain scans of older adults who exercise to bra...
(Date:11/27/2008)...nds the majority of acute lymphoblastic leukemia r...the time of diagnosis , , MEMPHIS, Tenn., N.... Jude Children,s Research Hospital have identifie...of children with acute lymphoblastic leukemia (ALL... to designing treatments for ALL relapse in childr...
Breaking Medicine Technology:Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3SemBioSys eligible to proceed with Phase I II plant produced insulin trial after submission of IND 7709 1SemBioSys eligible to proceed with Phase I II plant produced insulin trial after submission of IND 7709 2SemBioSys eligible to proceed with Phase I II plant produced insulin trial after submission of IND 7709 3Intact Medical Corporations Intact 28R 29 Excise XL Receives 510 28K 29 Marketing Clearance from the FDA 7708 1Intact Medical Corporations Intact 28R 29 Excise XL Receives 510 28K 29 Marketing Clearance from the FDA 7708 2BioCryst to Present at UBS 2008 Global Life Sciences Conference 7703 1BioCryst to Present at UBS 2008 Global Life Sciences Conference 7703 2BioCryst to Present at UBS 2008 Global Life Sciences Conference 7703 3Althea Technologies Secures 2412 M Credit Line to Continue Facility Growth and Expansion 7701 1Althea Technologies Secures 2412 M Credit Line to Continue Facility Growth and Expansion 7701 2
...mic Societies, Annual Meeting,This Month in Toront...y Technology Can Reduce the Risk Associated with R...e/ -- Masimo, the,inventor of Pulse CO-Oximetry an...etry, reported that a new independent study,presen...ual Meeting,in Toronto, Canada earlier this month ...
...y 30, 2007 - People with a,class of rare genetic d... death can be successfully treated with drugs, say...f Medicine and Lucile,Packard Children,s Hospital....year study that,prompt diagnosis coupled with a ra...y improves the survival rates of people with,the c...
Other Medicine Technology:Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology,Shown to Significantly Lower Instances of Severe Retinopathy of,Prematurity in Extremely Low Birth Weight Infants 2Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology,Shown to Significantly Lower Instances of Severe Retinopathy of,Prematurity in Extremely Low Birth Weight Infants 3Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology,Shown to Significantly Lower Instances of Severe Retinopathy of,Prematurity in Extremely Low Birth Weight Infants 4Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard,Researcher 2Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard,Researcher 3Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard,Researcher 4
(Date:12/1/2008)...ding when their DNA is damaged, in a process known...DNA from leading to unregulated cell division and ...in this week,s issue of PLoS Biology , has found ...teins into their surrounding environment. This cau...rt the development of age-related diseases includi...
(Date:12/1/2008)...at Memorial Sloan-Kettering Cancer Center, New Yor...xpression of genes for therapeutic purposes, and u...n mice. , Small, noncoding RNA molecules known a...xpression. In the study, the miRNA miR-181a was ha... cells known as T cells at different stages of the...
(Date:12/1/2008)...all/ - The Westaim Corporation today announced it ...s of NUCRYST Pharmaceuticals Corp. to consider a r...imately US$15 million or US$0.80 per share. Westai... the value of its 74.5 per cent stake in NUCRYST. ...ST,s Board of Directors has 20 days to call a meet...
(Date:12/1/2008)...- Media entrepreneur, television and,radio host R...ropist John,Bendheim will be honored by the Cedar...To A Cure" Gala, December 2, 2008, at the Hyatt Re... of the Board of Governors, co-chairs the,event w...olomon. The "Road To,A Cure" Gala is sponsored b...
Breaking Medicine News(10 mins):Health News:Escape cancer, but age sooner? The dark side of the tumor suppressing process 2Health News:The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders 2Health News:Cedars-Sinai Board of Governors to Honor Ryan Seacrest & John Bendheim at Annual 'Road To A Cure' Gala 2
...looks like Jessica Simpson is desperate to stun pe...tress reportedly shed around 11.3 kilograms in one...ne of 1,300-calorie-a-day, set by her celeb traine... she even got him to deliver the nutritional meals...
...en, across the globe, use a vast range of cosmetic...use is leading to a chemical pile up in their bodi...-up every day are soaking up nearly 5lb of chemica...dies. Many use over 20 different beauty products p...
...ording to a new report in the New England Journal ... drug entecavir can cause those who are also infe...st important drugs in the anti-HIV arsenal. the ...ected with both hepatitis B and HIV who was treate...
...earch study at University of Alberta ,shows a st...ence how elderly rural Albertans with congestive h...values may delay them from seeking help at critica...iew their work as a lifelong endeavour, and there ...
Other Medicine News:Health News:Excessive Use of Cosmetics Leads to Adverse Effects on the Body 2Health News:Challenges in Entecavir Drug Treatment 2Health News:Rural Work Ethic Curbs Elderly Heart Care 2
These are the Reusable Components (minus cannula), to be used with the VersaStep™ Plus Reposable Short System.
The VersaStep™ 5 mm and VersaStep™ PLUS Reposable system components for creating each access port are supplied in separate packages.
VersaStep™ Reposable Sterilization Trays.
VersaStep Plus Instrument for applications in laparoscopic procedures., ,The VERSASTEP™ Plus instrument with 100 mm working length is a unique non-bladed access device utilizing radial dilati
Medicine Products: